Suppr超能文献

韩国 1999-2017 年恶性卵巢生殖细胞肿瘤的发病和结局。

Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.

机构信息

Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Republic of Korea.

Division of Cancer Registration and Surveillance, National Cancer Center, Republic of Korea.

出版信息

Gynecol Oncol. 2021 Oct;163(1):79-84. doi: 10.1016/j.ygyno.2021.07.037. Epub 2021 Aug 12.

Abstract

OBJECTIVE

Malignant ovarian germ cell tumor (MOGCT) is a rare ovarian malignancy accounting for less than 5% of all ovarian cancers. We aimed to evaluate the incidence, survival, and subsequent malignancies after the diagnosis of MOGCT.

METHODS

Data from the Korea Central Cancer Registry were used to identify MOGCTs between 1999 and 2017. The age-standardized rates (ASRs), 5-year relative survival rates (RSR) and standardized incidence ratio (SIR) for subsequent cancer after diagnosis of MOGCT were estimated.

RESULTS

Of 2125 cases of newly diagnosed MOGCTs, 596 (28.0%) were diagnosed with dysgerminoma and 1529 (72.0%) with non-dysgerminoma. The ASR per 100,000 women-years was 0.539; ASR slightly increased over the study period (annual percent change [APC] = 1.01%; p = 0.02). There was an increase and decrease in the incidence of MOGCTs in the age groups 0-19 years (APC = 1.96%; p < 0.01) and ≥ 50 years (APC = -6.51%; p < 0.01), respectively. Patients with dysgerminoma showed significantly higher RSR than patients with non-dysgerminoma (98.0% vs. 94.9%, p < 0.01). Patients aged ≥50 years showed worst 5-year RSR (68.7%) than patients aged 0-19 years (97.8%) and 20-34 years (96.4%) (p < 0.01). The overall SIR for a subsequent cancer occurrence was 2.07, with the most frequent site of subsequent primary cancer being the thyroid (SIR = 2.78).

CONCLUSIONS

Our data demonstrated an excellent prognosis of MOGCTs among Korean women. There was a slight increase in MOGCT prevalence, which was more pronounced among those aged <19 years. After MOGCT diagnosis, the risk of developing a subsequent malignancy was doubled compared with the general population.

摘要

目的

卵巢恶性生殖细胞肿瘤(MOGCT)是一种罕见的卵巢恶性肿瘤,占所有卵巢癌的比例不到 5%。本研究旨在评估 MOGCT 的发病率、生存率以及诊断后的继发恶性肿瘤情况。

方法

利用韩国中央癌症登记处的数据,鉴定了 1999 年至 2017 年间的 MOGCT 病例。评估了 MOGCT 诊断后的继发恶性肿瘤的年龄标准化率(ASR)、5 年相对生存率(RSR)和标准化发病比(SIR)。

结果

在 2125 例新诊断的 MOGCT 患者中,596 例(28.0%)为生殖细胞瘤,1529 例(72.0%)为非生殖细胞瘤。每 10 万名女性年的 ASR 为 0.539;研究期间 ASR 略有上升(年变化百分比[APC]为 1.01%;p=0.02)。0-19 岁(APC=1.96%;p<0.01)和≥50 岁(APC=-6.51%;p<0.01)年龄组的 MOGCT 发病率分别呈上升和下降趋势。生殖细胞瘤患者的 RSR 明显高于非生殖细胞瘤患者(98.0% vs. 94.9%;p<0.01)。≥50 岁患者的 5 年 RSR 最差(68.7%),低于 0-19 岁患者(97.8%)和 20-34 岁患者(96.4%)(p<0.01)。总的继发恶性肿瘤 SIR 为 2.07,最常见的继发原发性肿瘤部位是甲状腺(SIR=2.78)。

结论

本研究中,韩国女性 MOGCT 的预后良好。MOGCT 的发病率略有上升,在<19 岁的人群中更为明显。诊断 MOGCT 后,发生继发恶性肿瘤的风险是普通人群的两倍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验